Format

Send to

Choose Destination
See comment in PubMed Commons below
Curr Opin Oncol. 2010 Sep;22(5):473-80. doi: 10.1097/CCO.0b013e32833b5126.

PARP inhibition: targeting the Achilles' heel of DNA repair to treat germline and sporadic ovarian cancers.

Author information

1
The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, Downs Road, Sutton, Surrey, UK.

Abstract

PURPOSE OF REVIEW:

Ovarian cancer remains the gynaecological malignancy with the highest mortality in the Western world. The strategy of identifying biologically distinct subgroups of ovarian cancer by means of clinical characteristics, histology and molecular profiling is an exciting prospect in personalizing and improving therapy for ovarian cancer.

RECENT FINDINGS:

Preclinical recognition that BRCA1 and BRCA2-associated tumours are very sensitive to inhibition of poly-ADP ribose polymerase (PARP), a key molecule in DNA repair, led to ovarian cancer patients with germline BRCA1 and BRCA2 mutations being treated with the PARP inhibitor olaparib (AZD2281, KU-0059436; KuDOS/Astra-Zeneca). The initial trials of olaparib in this patient population demonstrated an impressive rate of clinical benefit. Furthermore, tumours from patients with sporadic ovarian cancer have been found to commonly have somatic BRCA1 and BRCA2 mutations or other defects in DNA repair, with the implication that PARP inhibition may also have a role in treating these patients.

SUMMARY:

In this review, we discuss DNA repair mechanisms and strategies used to target them in oncology, our current experience with PARP inhibition in BRCA1 and BRCA2-mutation associated and sporadic ovarian cancer, as well as current issues in the clinical development of these agents.

PMID:
20485165
DOI:
10.1097/CCO.0b013e32833b5126
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wolters Kluwer
    Loading ...
    Support Center